Wir sind mit live! Mehr erfahren
0,5128 USD
-0,0220
4,11 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
0,5115
-0,0013
0,25 %
1 Tag
-4,11 %
5 Tage
-17,95 %
1 Monat
19,67 %
3 Monate
-18,86 %
6 Monate
-52,52 %
Seit Jahresbeginn
-41,74 %
1 Jahr
-65,12 %
5 Jahre
-89,23 %
10 Jahre
-89,23 %
 

Profil: Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.

Mitarbeiter: 17

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 25 %
Neutral 75 %
Negativ 0 %
Neutral
GlobeNewsWire
vor 3 Tagen
BullFrog AI to Present at the 20th Annual LD Micro Main Event on October 20, 2026
GAITHERSBURG, Md., Oct. 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using its proprietary platform to turn complex biomedical data into actionable insights, today announced Vin Singh, Founder and Chief Executive Officer, will participate in the 20th Annual LD Micro Main Event being held October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
BullFrog AI to Present at the 20th Annual LD Micro Main Event on October 20, 2026
Neutral
GlobeNewsWire
vor 10 Tagen
BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder
Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets
BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder
Positiv
Zacks Investment Research
vor 22 Tagen
Is Bullfrog AI Holdings Inc. (BFRG) Outperforming Other Medical Stocks This Year?
Here is how Bullfrog AI Holdings Inc. (BFRG) and Agilent Technologies (A) have performed compared to their sector so far this year.
Is Bullfrog AI Holdings Inc. (BFRG) Outperforming Other Medical Stocks This Year?
Positiv
Benzinga
vor 23 Tagen
BullFrog AI Stock Surges Wednesday: What's Happening?
BullFrog AI Holdings Inc. (NASDAQ:BFRG) shares are trading higher Wednesday morning following SEC filings revealing substantial open-market insider share purchases by both its Chief Executive Officer and Chief Financial Officer.
BullFrog AI Stock Surges Wednesday: What's Happening?
Neutral
Seeking Alpha
letzten Monat
Bullfrog AI Holdings, Inc. (BFRG) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Bullfrog AI Holdings, Inc. (BFRG) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Bullfrog AI Holdings, Inc. (BFRG) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Neutral
GlobeNewsWire
letzten Monat
BullFrog AI to Participate in September 2026 Investor Conferences
GAITHERSBURG, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces its participation in the following upcoming investor conferences.
BullFrog AI to Participate in September 2026 Investor Conferences
Neutral
GlobeNewsWire
vor 2 Monaten
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that the Company's management team will participate in the BTIG Virtual Biotechnology Conference being held on July 28-29, 2026.
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
Neutral
GlobeNewsWire
vor 2 Monaten
BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
GAITHERSBURG, Md., July 21, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that Vin Singh, Founder and Chief Executive Officer of BullFrog AI, will participate in the upcoming Water Tower Research Fireside Chat Series, taking place on Thursday, July 23, 2026 at 1:00 pm ET.
BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
Neutral
TheNewswire
vor 3 Monaten
Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"
June 24, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on BullFrog AI Holdings, Inc. (NASDAQ: BFRG) titled, “Helping Big Pharma Look Before It Leaps in Drug Discovery”. The report can be accessed here. BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a Gaithersburg, Maryland-based AI company that is focused on the pharmaceutical R&D market. BullFrog uses AI to increase the success rate of drug development while reducing the time and investment it requires. The company commercializes a proprietary, end-to-end AI and ML platform that prepares biomedical data, identifies the biological drivers of disease, and supports development decisions. The platform targets a core inefficiency in drug development: bringing a new drug to market typically takes 10-15 years and $1-2 billion, and even then, roughly half of the drugs that reach Phase 3 still fail, often because developers picked the wrong target or could not identify which patients a drug actually helps.
Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"
Neutral
GlobeNewsWire
vor 4 Monaten
BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced it has appointed commercial technology sales and scientific-focused leaders to support the momentum of the Company's commercial business driven growth strategy.
BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
Kursdiagramme mit Lightweight Charts™ umgesetzt